The trajectory of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial release generated significant returns, the expiration of its patent opened the floodgates https://haimazwbb101125.post-blogs.com/62692040/the-copyright-and-big-pharma-a-risky-investment